ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Coya Therapeutics Inc

Coya Therapeutics Inc (COYA)

7.125
0.035
( 0.49% )
Updated: 12:43:25

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
7.125
Bid
7.05
Ask
7.30
Volume
19,452
6.85 Day's Range 7.23
3.21 52 Week Range 10.6899
Market Cap
Previous Close
7.09
Open
6.85
Last Trade
20
@
7.0828
Last Trade Time
12:46:07
Financial Volume
$ 137,857
VWAP
7.0871
Average Volume (3m)
49,982
Shares Outstanding
14,618,172
Dividend Yield
-
PE Ratio
-13.09
Earnings Per Share (EPS)
-0.55
Revenue
6M
Net Profit
-7.99M

About Coya Therapeutics Inc

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-de... Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Coya Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker COYA. The last closing price for Coya Therapeutics was $7.09. Over the last year, Coya Therapeutics shares have traded in a share price range of $ 3.21 to $ 10.6899.

Coya Therapeutics currently has 14,618,172 shares outstanding. The market capitalization of Coya Therapeutics is $103.64 million. Coya Therapeutics has a price to earnings ratio (PE ratio) of -13.09.

COYA Latest News

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on...

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and...

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Expands on previously reported data showing the halting of disease progression in patients with ALS at six months and a corresponding reduction in inflammation, oxidative stress, and enhanced...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.035-0.4888268156427.167.486.75221477.06576551CS
41.21520.55837563455.917.955.815411366.93275196CS
12-1.715-19.40045248878.849.725.76499827.41665008CS
261.19520.15177065775.9310.68995.76733328.49393696CS
523.12578.125410.68993.21610717.20494164CS
1562.375504.7510.68993.21672796.32421934CS
2602.375504.7510.68993.21672796.32421934CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
POAIPredictive Oncology Inc
$ 1.718
(60.56%)
138.15M
SLRXSalarius Pharmaceuticals Inc
$ 3.43
(60.28%)
26.56M
PBMPsyence Biomedical Ltd
$ 0.595
(52.02%)
68.67M
VKTXViking Therapeutics Inc
$ 69.32
(37.51%)
13.24M
MIRAMIRA Pharmaceuticals Inc
$ 3.15
(33.47%)
37.31M
TWOU2U Inc
$ 1.58
(-61.65%)
4.12M
KDLYKindly MD Inc
$ 1.97
(-38.82%)
601.33k
CTNTCheetah Net Supply Chain Service Inc
$ 0.302
(-37.34%)
8.71M
EZFLEzFill Holdings Inc
$ 3.95
(-36.55%)
119.63k
SLGLSol Gel Technologies Ltd
$ 0.4601
(-31.33%)
13.36M
NVDANVIDIA Corporation
$ 116.50
(1.97%)
298.3M
SQQQProShares UltraPro Short QQQ
$ 8.86
(-2.21%)
168.15M
SLNASelina Hospitality PLC
$ 0.041
(-10.28%)
141.04M
POAIPredictive Oncology Inc
$ 1.718
(60.56%)
138.15M
PBMPsyence Biomedical Ltd
$ 0.595
(52.02%)
68.67M

COYA Discussion

View Posts
FooBarAndGrill FooBarAndGrill 1 week ago
Coya 8K July 15
On June 14, 2024, Coya Therapeutics, Inc. (the “Company”) submitted to the U.S. Food and Drug Administration (the “FDA”) an Investigational New Drug Application (the “IND”) seeking to initiate a study entitled “Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study with Additional 24-Week Open Label Extension (OLE) to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)” (the “Study”). On July 12, 2024, the Company received an email notification from the FDA stating that additional non-clinical data is required prior to the initiation of the Study. The FDA also stated that it would provide the Company with more details about what additional information it requires within the next thirty (30) days.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524178809/d762748d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 1 month ago
The WOW signal!
Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.
👍️0
FooBarAndGrill FooBarAndGrill 1 month ago
$COYA ALS Peer-Reviewed Publication:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1415106/full
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic intended to enhance regulatory T cell (Treg) function, announces the acceptance of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. A portion of the data from the manuscript was previously presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference and the 2024 Society of Neuroimmune Pharmacology Conference.
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93970259/coya-therapeutics-announces-acceptance-of-peer-rev
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Today 2 Jun is #LouGehrigDay #EndALS
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
It’s T+1 time
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
On May 17, 2024, Coya Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the Alzheimer’s Drug Discovery Foundation (the “ADDF”) for the issuance and sale in a private placement (the “Private Placement”) of 603,136 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”), at a purchase price of $8.29 per share for gross proceeds to the Company of $5.0 million.
ADDF >>>> https://www.alzdiscovery.org/
8K >>>>>>> https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524142950/d820823d8k.htm
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
Validating A Better ALS Biomarker With Coya's Fred Grossman
Fred discusses $COYA's 1H2024 plans for a IND application and the 2H2024 P2 trial.
https://www.clinicalleader.com/doc/validating-a-better-als-biomarker-with-coya-s-fred-grossman-0001
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-to-Participate-in-the-3rd-Annual-ALS-Drug-Development-Summit/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
And in the world of ALS.
Amylyx Pharmaceuticals said it would voluntarily remove its drug for amyotrophic lateral sclerosis from the market, a rare move that comes less than a month after a clinical trial showed its once-promising treatment for the fatal disease doesn’t work.
https://www.washingtonpost.com/business/2024/04/04/amylyx-als-drug/
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Investing in the fight against ALS. Hosted by Schwab Network.
https://schwabnetwork.com/video/investing-in-the-fight-against-als
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
COYA 2023 10-K
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033161/coya-20231231.htm
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000095017024033159/coya-20240319.htm
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Neuroimmune Pharmacology Conference Powerpoint
https://s201.q4cdn.com/307844724/files/doc_news/2024/NeuroimmunePharmacology3-12-2024-4.pdf
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
Dr. Stan Appel will be presenting during a 30-minute segment at the The 28th Society of Neuroimmune Pharmacology Conference.
March 10-13, 2024 The Francis Marion Hotel, Charleston
https://s-nip.org/documents/2024/SNIP_2024_Schedule.pdf
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
Empowering Patient Story and Coya’s Fight Against Neurodegenerative Diseases
Coya’s VP of Operations and Patient Advocacy, Daniel Barvin, had the opportunity to shed light on the world of his empowering patient story and Coya’s fight against neurodegenerative diseases in Houston for the Reel Abilities, UP Abilities event.
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
21 Feb: COYA letter to stockholders.
Today, we announce that we are further expanding the pipeline for COYA 302, adding Alzheimer’s disease (AD) to its growing list of indications
https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93327358/coya-therapeutics-issues-letter-to-stockholders-hi
👍️0
FooBarAndGrill FooBarAndGrill 5 months ago
About ALS:
ALS is a progressive disease, meaning the symptoms get worse over time. The functional status of ALS patients declines about 1 point per month on average, as measured by the Revised ALS Function Rating Scale1, or ALSFRS-R, a validated tool to monitor the progression of the disease.

COYA results:
Patients' disease progression was measured using the ALSFRS-R scale. The mean scores after initiation of treatment were not statistically different compared to the score at baseline, suggesting significant amelioration in the progression of the disease over the 48-week treatment period.

https://ih.advfn.com/stock-market/NASDAQ/coya-therapeutics-COYA/stock-news/93265319/coya-therapeutics-licenses-intellectual-property-r
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
SEC Form 4's
$COYA announced small option grants (5000 shr @ $7.41) for 3 BOD members. I expect more announcements to come.
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
8K 19 Jan 2024
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001835022/000119312524010775/d732822d8k.htm
As of December 31, 2023, Coya Therapeutics, Inc. (the “Company”) had cash and cash equivalents (unaudited) of $32.6 million. In January 2024, the Company received $7.5 million from Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”), as required under the terms of the Development and License Agreement entered into with Dr. Reddy’s on December 5, 2023, which was previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 6, 2023 (the “Form 8-K”).

The Company’s cash and cash equivalents as of December 31, 2023, pro forma for receipt of the $7.5 million from Dr. Reddy’s (as if such amount was received on December 31, 2023) would be $40.1 million.

In addition, as previously disclosed in the Form 8-K, (i) upon the first Food and Drug Administration (FDA) acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS), Dr. Reddy’s will pay the Company an additional $4.2 million, and (ii) upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy’s will pay the Company an additional $4.2 million.

The Company anticipates that the IND filing will be made in the first half of 2024 and the dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States will occur in the second half of 2024.

The Company expects its cash and cash equivalents described above will be sufficient to meet its operating needs into 2026.
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
$COYA current shares in issue: 10M
A Private placement announced DEC 5 2023 added 4.4M shares + 319K warrants.
Prospectus announced today will allow those shares to trade. The 319K warrants may also be exercised.
Currently most shares are held tightly.
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
I'm not much of a predictor. And most of the shares are tightly held.
But the company does have my respect and a good outlook long term.
👍️0
Sirpeter Sirpeter 6 months ago
Where do you see the PPS heading by year end
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in patients with ALS upon acceptance of the IND
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
Scientists solve 18-year-old mystery and find the once-elusive source of a critical T cell population
https://medicalxpress.com/news/2023-12-scientists-year-old-mystery-once-elusive-source.html
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
2023, $COYA has secured a private placement agreement plus a partnership agreement with $RDY. These two deals will provide non-dilutive financing thru 2026.
👍️0
FooBarAndGrill FooBarAndGrill 7 months ago
T-Cells are a focus of COYA research. Understanding the language is helpful.
CAR-T cells are Chimeric Antigen Receptors. (T-Cells)
Tregs are Regulatory T-Cells.
T-Cells have great potential.
‘It’s all gone’: CAR-T therapy forces autoimmune diseases into remission
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA updated Pipeline.
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
$COYA $26.5M private placement.
A very newsy 8-K
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
$COYA + $RDY

New collab announced.
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
$COYA Therapeutics has posted several YT videos.
https://www.youtube.com/@coyatherapeutics7911/videos
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Brief Hometown Houston interview with $COYA CEO Howard Berman.
https://cw39.com/news/health/new-study-at-houston-methodist-hospital-for-alzheimers-disease/
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
$COYA's web site does not provide a clear picture of on-going clinical trials. And the studies at clinicaltrials.net don't tie back to the company or COYA-301. Dear COYA, why not?
COYA 301 Phase 1 Trial NCT05821153
COYA 301 Phase 2 Trial NCT06096090
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
It's obvious $COYA is not in the hands of traders.
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA trading volume:
Friday recorded 60 trades for a total volume of 3.7K
Shares in issue 10.56m
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Coya News and events page:
https://ir.coyatherapeutics.com/news/default.aspx
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Coya will be presenting at at the 18th International Conference on Alzheimer’s & Parkinson’s Disease in Lisbon.
Coya Announces Acceptance of Oral Presentation
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
This completed P1 trial also tested COYA 301 (not by name) Low-Dose IL-2 administered SubQ.
NCT05821153
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Coya is associated with this P2 clinical trial:
NCT06096090
I'm not sure why COYA is not directly tagged on the page.
The drug being tested in Low-Dose IL-2 administered SubQ.
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA 301 is a new formulation of an existing drug: Proleukin® (aldesleukin).
Proleukin is designed to be administered by intravenous infusion.
COYA 301 is designed to be administered by subcutaneous injection.
Subcutaneous injection is intended for slow sustained absorption.
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA and other biotechs are focusing on Exosomes as a delivery mechanism.
Exosomes explained:
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA Cash: $10.9M Burn: $0.9M/Month
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA targets: Alzheimers and ALS
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
COYA area of expertise: Neurology
👍️0
FooBarAndGrill FooBarAndGrill 8 months ago
Welcome to the COYA stock message board. 1st test posting.
👍️0

Your Recent History

Delayed Upgrade Clock